Lmr Partners LLP Viridian Therapeutics, Inc.\De Transaction History

Lmr Partners LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$22.57 - $29.67 $225,700 - $296,700	-10,000 Reduced 50.0%	10,000 $237,000
Q1 2023 May 15, 2023	SELL	$25.04 - $37.6 $751,200 - $1.13 Million	-30,000 Reduced 60.0%	20,000 $508,000
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $173,020 - $273,994	9,213 Added 22.59%	50,000 $1.46 Million
Q3 2022 Nov 14, 2022	SELL	$10.7 - $25.5 $423,827 - $1.01 Million	-39,610 Reduced 49.27%	40,787 $837,000
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $263,799 - $524,837	27,623 Added 52.34%	80,397 $930,000
Q1 2022 May 16, 2022	BUY	$16.79 - $20.88 $190,969 - $237,489	11,374 Added 27.47%	52,774 $976,000
Q4 2021 Feb 14, 2022	BUY	$15.65 - $21.5 $123,509 - $169,678	7,892 Added 23.55%	41,400 $818,000
Q3 2021 Nov 15, 2021	BUY	$10.69 - $18.2 $358,200 - $609,845	33,508 New	33,508 $551,000

179

76.6M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $805M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Lmr Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Lmr Partners LLP with notifications on news.